Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JMJD6 | Q6NYC1 | 6/20 | 0.57 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 3/20 | 0.49 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | CA7 | P43166 | 3/20 | 0.49 |
| ▸ | CA9 | Q16790 | 3/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.49 |
| ▸ | JMJD7 | P0C870 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29466587 | 0.89 | JMJD6 (0.57) | JMJD6PIK3CACA12CA1CA2 | |
| SCHEMBL930636 | 0.89 | JMJD6 (0.57) | JMJD6PIK3CACA12CA1CA2 | |
| SCHEMBL8950955 | 0.88 | MMP2 (0.48) | JMJD6PIK3CAJMJD7LMNACYP1A2 | |
| SCHEMBL28528961 | 0.86 | JMJD6 (0.55) | JMJD6PIK3CACA12CA1CA2 | |
| SCHEMBL16578099 | 0.86 | KDM4E (0.61) | JMJD6PIK3CACA12CA1CA2 | |
| SCHEMBL6596814 | 0.85 | JMJD6 (0.49) | JMJD6PIK3CACA12CA1CA2 | |
| SCHEMBL6596817 | 0.85 | JMJD6 (0.49) | JMJD6PIK3CACA12CA1CA2 | |
| SCHEMBL28972534 | 0.84 | NPC1 (0.52) | JMJD6LMNACYP1A2CYP3A4NPC1 | |
| SCHEMBL13950719 | 0.82 | KDM4E (0.57) | JMJD6CA12CA1CA2CA7 | |
| SCHEMBL17144886 | 0.82 | JMJD6 (0.51) | JMJD6PIK3CACA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104804008-B | A kind of method of suitability for industrialized production methylsulfonic acid Telatinib | Yiteng Pharmaceutical (Taizhou) Co. Ltd. (CN) | 2016-03-23 | — | — | CN | claimed |
| CN-104804008-A | Industrial production method of telatinib mesylate | EDDINGPHARM TAIZHOU CO LTD | 2015-07-29 | — | — | CN | claimed |
| EP-2948458-B1 | BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2019-05-01 | — | — | EP | disclosed |
| US-9481682-B2 | Substituted benzamides and substituted pyridinecarboxamides as Btk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-11-01 | — | — | US | disclosed |
| CN-104804008-B | A kind of method of suitability for industrialized production methylsulfonic acid Telatinib | Yiteng Pharmaceutical (Taizhou) Co. Ltd. (CN) | 2016-03-23 | — | — | CN | disclosed |
| CN-104804008-B | A kind of method of suitability for industrialized production methylsulfonic acid Telatinib | Yiteng Pharmaceutical (Taizhou) Co. Ltd. (CN) | 2016-03-23 | — | — | CN | disclosed |
| US-20150353570-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-10 | — | — | US | disclosed |
| EP-2948458-A1 | BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-12-02 | — | — | EP | disclosed |
| CN-104804008-A | Industrial production method of telatinib mesylate | EDDINGPHARM TAIZHOU CO LTD | 2015-07-29 | — | — | CN | disclosed |
| WO-2014114185-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-07-31 | — | — | WO | disclosed |
| US-20140206681-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. | 2014-07-24 | — | — | US | disclosed |
| US-20080293696-A1 | 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-11-27 | — | — | US | disclosed |
| EP-1891047-A4 | 1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE AG (DE) | 2008-07-09 | — | — | EP | disclosed |
| EP-1891047-A2 | 1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS | Bayer HealthCare AG (DE) | 2008-02-27 | — | — | EP | disclosed |
| EP-1858893-A1 | 1,3-THIAZOLE-5-CARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS | Bayer Pharmaceuticals Corporation (US) | 2007-11-28 | — | — | EP | disclosed |
| EP-1765811-A2 | 2-AMINOARYLCARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS | Bayer Pharmaceuticals Corporation (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006133006-A2 | 1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE AG (DE) | 2006-12-14 | — | — | WO | disclosed |
| WO-2006096338-A1 | 1,3-THIAZOLE-5-CARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE AG (DE) | 2006-09-14 | — | — | WO | disclosed |
| WO-2006023707-A2 | 2-AMINOTHIOPHENECARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-03-02 | — | — | WO | disclosed |
| WO-2006002383-A2 | 2-AMINOARYLCARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206681-A1 | BTK INHIBITORS | BTK, SYK, LYN | JMJD6 1593/4885PIK3CA 73/4885CA12 4665/4885 |
| US-20080293696-A1 | 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents | ABCC3, HCCS, ABCC2 | JMJD6 2345/4885PIK3CA 951/4885CA12 2305/4885 |
| US-20150353570-A1 | BTK INHIBITORS | BTK, SYK, LYN | JMJD6 1593/4885PIK3CA 73/4885CA12 4665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.